Overview
Publication Venue For
The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.
2020
Insurance Payer Type and Patient Income Are Associated with Outcomes after Total Shoulder Arthroplasty.
47:589-596.
2020
The Rheumatologist's Role in Covid-19
2020
Factors influencing the effectiveness of allopurinol in achieving and sustaining target serum urate in a US Veterans Affairs gout cohort.
47:449-460.
2020
Construction of a frailty index as a novel health measure in systemic lupus erythematosus.
47:72-81.
2020
When has a knee or hip replacement failed? A patient perspective.
2019
Fatigue measurements in systemic lupus erythematosus.
46:1470-1477.
2019
How Systemic Sclerosis Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty.
2019
Addressing challenges in developing a core domain set in adherence interventions in rheumatology: A report from the OMERACT-Adherence Group.
46:1202-1206.
2019
Identifying provisional generic contextual factor domains for clinical trials in rheumatology: Results from an OMERACT initiative.
46:1159-1163.
2019
Rates of total joint replacement in the United States: Future projections to 2020-2040 using the national inpatient sample.
46:1134-1140.
2019
Core domain Set selection according to OMERACT filter 2.1: The OMERACT methodology.
46:1014-1020.
2019
Establishing an updated core domain set for studies in juvenile idiopathic arthritis: A report from the OMERACT 2018 JIA workshop.
46:1006-1013.
2019
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT premeeting toward consensus on core sets for randomized controlled trials.
46:1053-1058.
2019
Instrument selection using the OMERACT filter 2.1: The OMERACT methodology.
46:1028-1035.
2019
OMERACT filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies.
46:1021-1027.
2019
The Third Biennial 2018 OMERACT First-time Participant Program: A qualitative and quantitative study.
46:1036-1040.
2019
Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States.
46:237-244.
2019
HLA-DRB1 amino acid positions and residues associated with antibody-positive rheumatoid arthritis in black south africans.
46:138-144.
2019
Juvenile idiopathic arthritis: An idea whose time has gone?.
46:124-126.
2019
Fertility and ovarian reserve among women with rheumatoid arthritis.
46:455-459.
2019
OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.
46:1409-1414.
2019
Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
46:492-500.
2019
Pain measurement in rheumatic and musculoskeletal diseases: Where to go from here? Report from a special interest group at OMERACT 2018.
46:355-1359.
2019
Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor.
46:475-482.
2019
Predictors of remission and low disease activity state in systemic lupus erythematosus: Data from a multiethnic, multinational Latin American cohort.
46:1299-1308.
2019
Standardizing terminology and assessment for orofacial conditions in juvenile idiopathic arthritis: International, multidisciplinary consensus-based recommendations.
46:518-522.
2019
Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in Juvenile idiopathic arthritis.
45:1301-1307.
2018
Adiposity in juvenile psoriatic arthritis.
45:411-418.
2018
Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus.
45:393-396.
2018
Variability in the reporting of serum urate and flares in gout clinical trials: Need for minimum reporting requirements.
45:419-424.
2018
Trends in joint replacement surgery in patients with rheumatoid arthritis.
45:158-164.
2018
Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: The first year after diagnosis.
45:107-114.
2018
Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritis.
45:40-44.
2018
Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group report.
44:1894-1898.
2017
Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: Report from a special interest group at OMERACT 2016.
44:1884-1888.
2017
Validating rheumatoid arthritis remission using the patients' perspective: Results from a special interest group at OMERACT 2016.
44:1889-1893.
2017
Achieving consensus on total joint replacement trial outcome reporting using the OMERACT filter: Endorsement of the final core domain set for total hip and total knee replacement trials for endstage arthritis.
44:1723-1726.
2017
Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group.
44:1727-1733.
2017
Isolated arthritis of the temporomandibular joint as the initial manifestation of juvenile idiopathic arthritis.
44:1632-1635.
2017
Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets.
44:1551-1559.
2017
Malignancy in pediatric-onset systemic lupus erythematosus.
44:1484-1486.
2017
The OMERACT first-time participant program: Fresh eye from the new guys.
44:1560-1563.
2017
Outcome measures used in arthroplasty trials: Systematic review of the 2008 and 2013 literature.
44:1277-1287.
2017
Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.
44:1083-1087.
2017
Weathering a macrophage storm.
44:970-972.
2017
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infection.
44:565-570.
2017
The effect of widespread pain on knee pain worsening, incident knee osteoarthritis (OA), and incident knee pain: The multicenter OA (MOST) study.
44:493-498.
2017
Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: A survey of the childhood arthritis and rheumatology research alliance.
44:352-360.
2017
Clinical orofacial examination in juvenile idiopathic arthritis: International consensus-based recommendations for monitoring patients in clinical practice and research studies.
44:326-333.
2017
The juvenile psoriatic arthritis cohort in the CARRA registry: Clinical characteristics, classification, and outcomes.
44:342-351.
2017
Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review.
43:1997-2009.
2016
Treatments for lupus nephritis: A systematic review and network metaanalysis.
43:1801-1815.
2016
The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013.
43:1755-1762.
2016
Time trends, predictors, and outcome of emergency department use for gout: A nationwide US study.
43:1581-1588.
2016
Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.
43:1027-1029.
2016
Prospecting for precision: Promises for personalized medicine.
43:999-1000.
2016
Ms. A.M. Taylor, et al reply.
43:826.
2016
The performance and association between patient-reported and performance-based measures of physical functioning in research on individuals with arthritis.
43:131-137.
2016
Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group.
42:2460-2464.
2015
Outcome domains and measures in total joint replacement clinical trials: Can we harmonize them? An OMERACT collaborative initiative.
42:2496-2502.
2015
Toward ensuring health equity: Readability and cultural equivalence of OMERACT patient-reported outcome measures.
42:2448-2459.
2015
Consensus on the need for a hierarchical list of patient-reported pain outcomes for metaanalyses of knee osteoarthritis trials: An OMERACT objective.
42:1971-1975.
2015
Current state of reporting pain outcomes in cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda.
42:1934-1942.
2015
Harmonizing pain outcome measures: Results of the pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the cochrane musculoskeletal group and OMERACT.
42:1943-1946.
2015
Is chronic pain a disease in its own right? Discussions from a pre-OMERACT 2014 workshop on chronic pain.
42:1947-1953.
2015
No association between daily walking and knee structural changes in people at risk of or with mild knee osteoarthritis. prospective data from the multicenter osteoarthritis study.
42:1685-1693.
2015
A call for evidence-based decision making when selecting outcome measurement instruments for summary of findings tables in systematic reviews: Results from an OMERACT working group.
42:1954-1961.
2015
An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users.
42:1478-1483.
2015
Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group technique.
42:1616-1623.
2015
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
42:994-1001.
2015
Do "evidence-based recommendations" need to reveal the evidence? Minimal criteria supporting an "evidence claim".
42:1737-1739.
2015
Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?.
42:1078-1080.
2015
Is the double contour sign specific for gout? Or only for crystal arthritis?.
42:353-354.
2015
Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis.
42:2155-2159.
2015
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
42:504-512.
2015
Optimal strategies for reporting pain in clinical trials and systematic reviews: Recommendations from an OMERACT 12 workshop.
42:1962-1970.
2015
Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.
42:541-546.
2015
The OMERACT first-time participant ("Newbie") program: Initial assessment and lessons learned.
42:1976-1981.
2015
Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
41:1935-1943.
2014
Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.
41:2078-2084.
2014
Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.
41:216-226.
2014
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
41:300-309.
2014
Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences.
41:206-215.
2014
Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses.
41:194-205.
2014
American college of rheumatology criteria at inception, and accrual over 5 years in the slicc inception cohort.
41:875-880.
2014
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.
41:574-580.
2014
Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
41:113-118.
2014
Does clinically important change in function after knee replacement guarantee good absolute function? the multicenter osteoarthritis study.
41:60-64.
2014
How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
41:1025-1030.
2014
Including health equity considerations in development of instruments for rheumatology research: An introduction to a novel OMERACT paradigm.
41:150-152.
2014
Introduction: OMERACT 11 - International consensus conference on outcome measures in rheumatology clinical trials.
41:145-149.
2014
OMERACT endorsement of measures of outcome for studies of acute gout.
41:569-573.
2014
Outcome measures in acute gout: A systematic literature review.
41:558-568.
2014
Reliability and clinically important improvement thresholds for osteoarthritis pain and function scales: A multicenter study.
41:509-515.
2014
Research priorities in gout: The patient perspective.
41:615-616.
2014
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studies.
41:837-852.
2014
The diagnostic performance of anterior knee pain and activity-related pain in identifying knees with structural damage in the patellofemoral joint: The Multicenter Osteoarthritis Study.
41:1695-1702.
2014
Updating the OMERACT Filter: Core areas as a basis for defining core outcome sets.
41:994-999.
2014
Updating the OMERACT filter: Implications for imaging and soluble biomarkers.
41:1016-1024.
2014
Updating the omeract filter: Discrimination and feasibility.
41:1005-1010.
2014
Updating the omeract filter: Implications of filter 2.0 to select outcome instruments through assessment of "truth": Content, face, and construct validity.
41:1000-1004.
2014
Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.
40:1812-1822.
2013
Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfect.
40:1640-1642.
2013
High doses of infliximab in the management of juvenile idiopathic arthritis.
40:1749-1755.
2013
A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria (Journal of Rheumatology (2013) 40, (498-505)).
40:1634.
2013
Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis.
40:1498-1504.
2013
Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.
40:1218-1225.
2013
Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the childhood arthritis and rheumatology research alliance (CARRA) registry.
40:936-942.
2013
Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry.
40:842-849.
2013
Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial.
40:572-578.
2013
Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome.
40:743-744.
2013
A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria.
40:498-505.
2013
Shrinking lung syndrome as a manifestation of pleuritis: A new model based on pulmonary physiological studies.
40:273-281.
2013
Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.
40:127-136.
2013
Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry.
39:2341-2351.
2012
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA registry.
39:1867-1874.
2012
Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.
39:1880-1887.
2012
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
39:1632-1640.
2012
Genetic risk factors for thrombosis in systemic lupus erythematosus.
39:1603-1610.
2012
Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials.
39:1450-1457.
2012
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial.
39:1326-1333.
2012
Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease.
38:2675-2681.
2011
Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.
38:2274-2275.
2011
Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis.
38:2272-2273.
2011
Smoking and outcomes after knee and hip arthroplasty: A systematic review.
38:1824-1834.
2011
Arthritis increases the risk for fractures - Results from the women's health initiative.
38:1680-1688.
2011
Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working Group.
38:1745-1750.
2011
Bringing it all together: A novel approach to the development of response criteria for chronic gout clinical trials.
38:1467-1470.
2011
Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis study.
38:1390-1395.
2011
Early postoperative mortality following joint arthroplasty: A systematic review.
38:1507-1513.
2011
Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial (The Journal of Rheumatology (2010) 37, (2377-86)).
38:1534.
2011
Patient-reported outcomes in chronic gout: A report from OMERACT 10.
38:1452-1457.
2011
Serum urate in chronic gout - Will it be the first validated soluble biomarker in rheumatology?.
38:1462-1466.
2011
Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities.
38:1458-1461.
2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial.
38:990-996.
2011
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.
38:764-768.
2011
Surgery for shoulder osteoarthritis: A cochrane systematic review.
38:598-605.
2011
Botulinum toxin for shoulder pain: A cochrane systematic review.
38:409-418.
2011
The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility.
38:446-449.
2011
Disease phenotypes and gender association of FCRL3 single-nucleotide polymorphism -169T/C in Taiwanese patients with systemic lupus erythematosus and rheumatoid arthritis.
38:264-270.
2011
Combination therapy of abatacept and in children with refractory systemic juvenile idiopathic arthritis: A retrospective case series.
38:180-181.
2011
Tocilizumab for rheumatoid arthritis: A cochrane systematic review.
38:10-20.
2011
Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial.
37:2377-2386.
2010
Spondyloarthritis in a pediatric population: Risk factors for sacroiliitis.
37:2402-2408.
2010
Clinically important improvement in function is common in people with or at high risk of knee OA: The MOST study.
37:1244-1251.
2010
Golimumab for rheumatoid arthritis: A systematic review.
37:1096-1104.
2010
Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens.
37:870-875.
2010
(Journal of Rheumatology (2009) 36, (2114) DOI:10.3899/jrheum.090591).
37:681.
2010
Abatacept for rheumatoid arthritis: A cochrane systematic review (Journal of Rheumatology (2010) 37, (234-245) DOI:10.3899/jrheum.091066).
37:682.
2010
Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritis.
37:275-281.
2010
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.
37:167-174.
2010
Abatacept for rheumatoid arthritis: A cochrane systematic review.
37:234-245.
2010
Assessment of the methodologic quality of medical and surgical clinical trials in patients with arthroplasty.
36:2642-2654.
2009
What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: A pooled analysis of 4 randomized placebo-controlled trials of duloxetine.
36:2517-2522.
2009
Assessing single joints in arthritis clinical trials.
36:2092-2096.
2009
Discordance between self-report of physician diagnosis and administrative database diagnosis of arthritis and its predictors.
36:2000-2008.
2009
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial.
36:1705-1714.
2009
Anakinra for rheumatoid arthritis: A systematic review.
36:1118-1125.
2009
Spondyloarthritis is associated with poor function and physical health-related quality of life.
36:1012-1020.
2009
Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis.
36:106-112.
2009
Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.
36:82-88.
2009
How to ascertain drug safety in the context of benefit. Controversies and concerns.
36:2114-2121.
2009
Evaluation of an instrument assessing influence of gout on health-related quality of life.
35:2406-2414.
2008
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.
35:2355-2358.
2008
A new approach yields high rates of radiographic progression in knee osteoarthritis.
35:2047-2054.
2008
Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).
35:343-348.
2008
Neither cell-surface nor soluble CD154 levels are associated with coronary artery disease in systemic lupus erythematosus.
35:359-360.
2008
Does medical insurance matter in the progression to endstage renal disease among patients with lupus nephritis?.
34:1953-1954.
2007
Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada.
34:1918-1924.
2007
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.
34:1133-1138.
2007
Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [3].
34:234.
2007
Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.
33:2330-2336.
2006
Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.
33:2081-2084.
2006
Trends in prevention of glucocorticoid-induced osteoporosis.
33:1651-1657.
2006
Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-α therapy [1].
33:825.
2006
Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting system.
33:562-566.
2006
Treatment of pediatric localized scleroderma with methotrexate.
33:609-614.
2006
Patterns of use and public perception of over-the-counter pain relievers: Focus on nonsteroidal antiinflammatory drugs.
32:2218-2224.
2005
Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.
32:2150-2155.
2005
Pain-related beliefs and affective pain responses: Implications for ethnic disparities in preferences for joint arthroplasty.
32:1149-1152.
2005
Effect of ethnicity on disease activity in systemic lupus erythematosus [1] (multiple letters).
32:962-963.
2005
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture.
32:870-875.
2005
Swallowing difficulties from "DISH-phagia".
31:2526-2527.
2004
The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
31:1934-1940.
2004
Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis.
31:1693-1697.
2004
Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid- naïve patients.
31:1281-1285.
2004
Recent Approaches to Understanding Osteoarthritis Pain.
31:54-60.
2004
Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices.
30:2680-2688.
2003
A 2-Phase Screening Process for Patients with Wegener's Granulomatosis: A Pilot Study.
30:2420-2421.
2003
Health related quality of life in women with elderly onset rheumatoid arthritis.
30:952-957.
2003
OMERACT 6 brings new perspectives to rheumatology measurement research.
30:639-641.
2003
Balancing bones and bucks among new glucocorticoid users.
30:1-3.
2003
Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imaging.
29:2463-2465.
2002
Significance of increased circulating proteasome in autoimmune disease.
29:2027-2030.
2002
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women.
29:246-254.
2002
Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: The Framingham Osteoarthritis Study.
29:161-165.
2002
MTX affects inflammation and tissue destruction differently in the rat AA model.
28:1476-1481.
2001
Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.
28:1298-1305.
2001
Women in rheumatology [1].
28:1735-1736.
2001
Occurrence of scleroderma in monozygotic twins.
27:2267-2269.
2000
The impact of women in the practice of academic and clinical rheumatology in the Americas.
27:1827-1829.
2000
Nabumetone induced pseudoporphyria in childhood [3] (multiple letters).
27:1817-1818.
2000
Nabumetone induced pseudoporphyria in childhood..
27:1817-1818.
2000
Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis.
27:1038-1044.
2000
Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline.
27:530-534.
2000
Expression of the precursor of secretoneurin, secretogranin II, in the synovium of patients with rheumatoid arthritis and osteoarthritis.
27:2347-2350.
2000
Current treatment by United States and Canadian pediatric rheumatologists.
26:2036-2038.
1999
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug [1] (multiple letters).
26:2280-2281.
1999
Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis.
26:1065-1067.
1999
Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: Disease remissions and changes in diagnoses in well established and undifferentiated CTD.
26:816-825.
1999
Self-administered joint counts in rheumatoid arthritis: Comparison with standard joint counts.
26:536-539.
1999
Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.
26:259-261.
1999
Folic acid supplementation prevents deficient blood [1] (multiple letters).
25:2473.
1998
Familial painful restless legs syndrome correlates with pain dependent variation of blood flow to the caudate, thalamus, and anterior cingulate gyrus.
25:2270-2275.
1998
Enhanced expression of immunoglobulin κ light chains with unusually long CDR3 regions in patients with rheumatoid arthritis.
25:1067-1071.
1998
Septic arthritis caused by Neisseria sicca..
25:826-828.
1998
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention.
25:441-446.
1998
Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: Disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases.
25:261-268.
1998
Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.
25:221-228.
1998
A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial.
24:1910-1915.
1997
Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone..
24:1849-1850.
1997
Childhood sarcoidosis--does age of onset predict clinical manifestations?.
24:1654-1656.
1997
Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) trial.
24:1295-1302.
1997
Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis [3].
23:2184-2185.
1996
Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis.
23:1849-1855.
1996
Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis.
23:1845-1848.
1996
Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of phase I dose escalation study.
23:1353-1362.
1996
Systemic lupus erythematosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors.
23:469-475.
1996
Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly.
22:2142-2147.
1995
Reiter's syndrome associated with cryptosporidial gastroenteritis.
22:1962-1963.
1995
Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.
21:1457-1462.
1994
Arthroscopic evaluation of knee articular cartilage: A comparison with plain radiographs and magnetic resonance imaging.
21:675-679.
1994
Survival impact of autoantibodies in systemic lupus erythematosus.
21:224-228.
1994
Functional magnetic resonance imaging should be included in the evaluation of the cervical spine in patients with rheumatoid arthritis.
20:1485-1488.
1993
Meta analysis of the effect of methotrexate on radiologic progression in rheumatoid arthritis [1].
20:1623.
1993
Anticardiolipin antibodies in systemic lupus erythematosus: Clinical correlates, HLA associations, and impact on survival.
20:1684-1693.
1993
Folic acid supplementation during methotrexate therapy: It makes sense.
20:929-930.
1993
Sternoclavicular brucellar arthritis: A report of 7 cases and a review of the literature.
20:1184-1186.
1993
Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: A meta-analysis.
19:1868-1873.
1992
Digital subtraction radiography for the assessment of bone changes in rheumatoid arthritis.
19:1697-1703.
1992
Expressing our inner thoughts: How to organize and write a clinical research project grant application.
19:16-19.
1992
Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.
19:1207-1211.
1992
Mechanisms of pathogenesis in scleroderma. II. Effects of serum and conditioned culture medium on fibroblast function in scleroderma.
19:1212-1219.
1992
Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia.
19:1191-1194.
1992
Subcutaneous pancreatic fat necrosis associated with acute arthritis.
19:630-632.
1992
Disease and psychosocial factors related to physical functioning in rheumatoid arthritis.
18:1150-1157.
1991
Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease.
18:1332-1339.
1991
Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.
18:1340-1343.
1991
Monthly cyclophosphamide in lupus pneumonitis and myositis.
18:153.
1991
Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?.
18:984-988.
1991
Activated lymphocytes in peripheral blood of patients with RA.
17:1712.
1990
An eosinophilia-myalgia syndrome associated with an L-tryptophan containing product.
17:1551-1553.
1990
Eosinophilic myositis an expression of L-tryptophan toxicity?.
17:1554-1556.
1990
Mortality vs quality of life (I).
17:1110.
1990
The value of the Norgaard view in the evaluation of erosive arthritis.
17:614-617.
1990
Cognitive-behavioral therapy for primary fibromyalgia.
16:131-136.
1989
Discriminant and convergent validity of self-report measures of affective distress in patients with rheumatoid arthritis.
16:1428-1432.
1989
Thrombotic thrombocytopenic purpura in systemic sclerosis..
16:1400-1401.
1989
AS and a 9.2 kb Pvu II class I HLA DNA restriction fragment..
16:141-142.
1989
Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: A controlled study.
16:890-896.
1989
Lupus pneumonitis and anti-SSA(Ro) antibodies.
16:479-481.
1989
Methotrexate-induced liver abnormalities in rheumatoid arthritis.
16:1180-1183.
1989
Rheumatoid arthritis in American blacks: A clinical and radiological study.
16:1197-1200.
1989
Septic arthritis due to Mycobacterium phlei presenting as infantile Reiter's syndrome.
16:1377-1378.
1989
Severe reversible interstitial pneumonitis induced by low dose methotrexate.
16:1007-1008.
1989
Articular involvement in human brucellosis..
15:379-380.
1988
Etiopathogenesis of rheumatoid arthritis-like disease in MRL/1 mice: II. Ultrastructural basis of joint destruction.
15:10-16.
1988
The value of the joint alignment and motion scale in rheumatoid arthritis.
15:1212-1215.
1988
Transient osteoporosis of the hip: Magnetic resonance imaging.
14:1184-1189.
1988
The arthritis of brucellosis: a perspective one hundred years after Bruce's discovery..
14:1083-1085.
1987
The assessment of pain in rheumatoid arthritis: Disease differentiation and temporal stability of a behavioral observation method.
14:700-704.
1987
Sexual quality-of-life of patients with arthritis compared to arthritis-free controls.
14:570-576.
1987
Toxicity to methotrexate in rheumatoid arthritis.
14:74-79.
1987
Genetic and molecular genetic studies of murine and human lupus..
14 Suppl 13:166-176.
1987
Toxicity due to remission inducing drugs in RA..
14:175-176.
1987
Development of clinical criteria for osteoarthritis.
14:3-6.
1987
Evaluation of the American Rheumatism Association preliminary criteria for remission in rheumatoid arthritis: A prospective study.
14:93-96.
1987
Meeting highlights: Workshop on epidemiology of the rheumatic diseases in the Americas.
13:810-813.
1986
Tuberculous podagra..
12:1022-1024.
1985
Paracoccidioides brasiliensis arthritis. Report of a case and review of the literature.
12:356-358.
1985
The carpometacarpal ratio: A useful method for assessing disease progression in rheumatoid arthritis.
12:846-848.
1985
Study of HLA antigens in ten multiple-case rheumatoid arthritis families.
11:129-135.
1984
Immune complexes and clinical manifestations in patients with rheumatoid arthritis..
11:245-246.
1984
Local synthesis of IgM and IgM rheumatoid factor in rheumatoid pleuritis.
10:204-209.
1983
DR antigen distribution in blacks with rheumatoid arthritis.
10:579-583.
1983
Reactive arthritis associated with brucellosis: HAL studies.
8:621-625.
1981
